Lecicarbon E Co2-Laxans (Sodium Hydrogen Carbonate, Sodium Dihydrogen Phosphate)

Sodium hydrogen carbonate, together with sodium dihydrogen phosphate, creates an osmotic gradient in the rectal lumen. This gradient draws water from surrounding tissues into the colon, expanding stool volume and stimulating stretch receptors that trigger peristalsis, ultimately facilitating bowel movement.

The specific dose and volume of Lecicarbon E Co2-Laxans are determined by the prescribing healthcare professional based on the patient’s condition, age, and response. The prescriber will provide detailed instructions on the amount to be administered and the frequency of use.

Safety data for Lecicarbon E Co2-Laxans in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing it to pregnant or breastfeeding individuals. Consultation with a medical professional is essential.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details (including any cold‑chain requirements), and required import documentation.

Lecicarbon E Co2-Laxans uses a combination of sodium hydrogen carbonate and sodium dihydrogen phosphate, whereas many alternatives such as polyethylene glycol rely on larger polymer molecules. Both create an osmotic effect, but the enema formulation of Lecicarbon E provides rapid local action, while oral agents act systemically and may have a slower onset.

Store the enema at room temperature, preferably below 25 °C. Keep the container tightly sealed, protect it from moisture, direct sunlight, and extreme temperatures. Do not freeze the solution, and ensure the packaging remains intact until use.

The product is administered rectally as an enema. The prescribed volume is drawn into a suitable applicator, the patient assumes a comfortable position (e.g., left lateral), and the solution is gently introduced into the rectum. The patient should retain the enema for the time specified by the prescriber to allow the laxative effect to occur.

Serious risks include severe dehydration, marked electrolyte disturbances (especially sodium or phosphate imbalances), rectal bleeding, and rare allergic reactions that may present as rash, swelling, or breathing difficulty. Patients should seek immediate medical attention if any of these symptoms develop.

The enema is contraindicated in individuals with known intestinal obstruction, severe dehydration, active rectal disease (such as ulcerative colitis flare), or hypersensitivity to any component of the formulation. It should also be used with caution in patients with significant electrolyte disorders or renal impairment.